Oncternal Therapeutics (NASDAQ:ONCT – Free Report) had its price target reduced by HC Wainwright from $19.00 to $18.00 in a report issued on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock.
Separately, StockNews.com initiated coverage on shares of Oncternal Therapeutics in a research report on Wednesday, August 7th. They set a hold rating on the stock.
Check Out Our Latest Report on Oncternal Therapeutics
Oncternal Therapeutics Stock Up 2.0 %
Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($2.89) EPS for the quarter, beating analysts’ consensus estimates of ($3.03) by $0.14. Oncternal Therapeutics had a negative net margin of 3,160.73% and a negative return on equity of 107.67%. The company had revenue of $0.80 million for the quarter, compared to analyst estimates of $0.24 million. During the same quarter last year, the firm posted ($3.00) earnings per share. Research analysts predict that Oncternal Therapeutics will post -11.63 EPS for the current fiscal year.
Hedge Funds Weigh In On Oncternal Therapeutics
A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned 0.84% of Oncternal Therapeutics at the end of the most recent quarter. 16.05% of the stock is owned by hedge funds and other institutional investors.
About Oncternal Therapeutics
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
Featured Stories
- Five stocks we like better than Oncternal Therapeutics
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Brinker International’s Price Dip is an Appetizing Entry Point
- What is the S&P/TSX Index?
- 3 Stocks That Could Beat the September Blues
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.